Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Cancer immunotherapy: no prior antibiotic treatment
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Cancer immunotherapy: no prior antibiotic treatment
Gastroenterology

Cancer immunotherapy: no prior antibiotic treatment

Cancer
Oncology Gastroenterology

Gut dysbiosis caused by the prior use of broad-spectrum antibiotics could impact the efficacy of cancer immunotherapy, in turn leading to a decrease in overall patient survival.

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail
Actu PRO: Immunothérapie et cancer : pas d’antibiothérapie préalable

About this article

Created 16 December 2019
Updated 06 October 2021

 

Immune checkpoint inhibitor (ICI) therapy is a form of immunotherapy that provides a new therapeutic option against some tumors, such as melanoma and non-small-cell lung cancer (NSCLC). Despite its efficacy, only a small number of patients can benefit from it. That is why it is important to better anticipate the response to treatment and improve routine prescription guidelines. To this end, a team of researchers investigated if the time of administration of broad-spectrum antibiotics (ATB) which are mainly used to treat respiratory infections–either prior or concomitantly to ICI– could have an impact on the treatment efficacy through gut microbiota modulation.

Patient survival decreased from 26 to 2 months

This prospective cohort study, conducted at 2 teaching hospitals, included 196 patients (137 male and 59 female, average age: 68 years) with cancer (119 NSCLC, 38 melanoma and 39 other types of cancer) who received ICI therapy for more than three years. The results indicate that antibiotic therapy given in the 30 days prior to ICI therapy (pATB, i.e prior antibiotics) clearly decreases overall patient survival, regardless of the type of cancer (2 months for patients who received pATB vs. 26 months for those who did not receive any prior antibiotic treatment). The percentage of tumors refractory to therapy is also considerably higher in patients who received pATB (81% vs. 44%). In conclusion, the time of administration of antibiotics seems crucial: while it does not have any negative impact if given concomitantly to ICI therapy, it worsens the prognosis when it is administered previously.

Understanding the role of the gut microbiota

The authors are aware that their results are limited by the small cohort size and by the lack of correlation analysis between antibiotic therapy and composition of the patients’ microbiota. But they are in line with results from previous studies indicating that gut dysbiosis is associated to a poor response to ICI therapy against cancer. One possible explanation is that the use of antibiotics could lead to long-lasting disruptions in the gut ecosystem which would then jeopardize the efficacy of T cells against cancer. However, this is still an imprecise hypothesis, and mechanistic studies should be carried out as soon as possible in order to understand how gut microbiota alterations induced by prior antibiotic use negatively impact the efficacy of ICI therapy.

 

Sources

Pinato DJ, Howlett S, Ottaviani D et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019 Dec 1;5(12):1774-1778.

Tags
Drug interaction Antibiotics Antibiotic therapy Antibiotic ICI Cancer Immunotherapy

en_view en_sources

    Created 16 December 2019
    Updated 06 October 2021

    About this article

    To know more about this topic.

    Main topic

    Cancer

    Medical practice

    Oncology Gastroenterology

    Content type

    News
    Gastroenterology

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irritable Bo...

    Find out more

    Human milk nutrient fortifiers alter the developing gastrointestinal microbiota of very-low-birth-weight infants

    Commented article - Children's section By Pr. Emmanuel M...

    Find out more

    Impact of beer and non alcoholic consumption on the gut microbiota

    By Pr. Bernd SchnablDivision of Gastroenterology, San Diego Digestive Diseases Research Center (SDDRC), UC ...

    Find out more

    Everything you need to know about Irritable Bowel Syndrome (IBS)

    Accrediting training, infographics, expert’s video, thematic folder, news… Biocodex Microbiota Institute pr...

    Find out more

    Gut Microbiota #17

    By Pr. Satu PekkalaAcademy of Finland Research Fellow, Faculty of Sport and Health Sciences, University of ...

    Find out more

    Gut Microbiota # 16

    By Pr. Satu PekkalaAcademy of Finland Research Fellow, Faculty of Sport and Health Sciences, University of ...

    Find out more

    Highlights from the UEGW

    By Dr. Lucas WautersGastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium

    Find out more

    The Gut-Brain axis

    By Pr. Sarkis K. Mazmanian, John W. Bostick, Nadia SuryawinataBiology and Biological Engineering, Californi...

    Find out more

    Continue reading

    News
    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article
    Parkinson : le microbiote intestinal, chef d’orchestre des mécanismes pathogéniques ?
    27.02.2023

    Does the gut microbiota orchestrate pathogenic mechanisms in Parkinson’s disease?

    Read the article
    Everything you need to know about Microbiota & Immunity
    15.09.2022

    Everything you need to know about Microbiota & Immunity

    Read the article
    The psychobiotic diet: modulating gut microbiota to reduce stress
    13.02.2023

    The psychobiotic diet: modulating gut microbiota to reduce stress

    Read the article
    30.01.2023

    Schizophrenia and aggressive behavior: what involvement of the intestinal microbiota?

    Read the article
    23.01.2023

    Idiopathic urethritis in men: new infectious etiologies?

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo